Novartis said the spinoff operation, which require final board endorsement and approval by shareholders, is expected to be completed in the second half of 2023.
Details of law firms acting for Novartis and Sandoz on the deal were not immediately available.
The Sandoz company that will exist after the separation — which Novartis said would be the number one generic drugs company in Europe, with…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
- Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
- Create custom alerts for specific article and case topics and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
